RTsafe and CNAO Next Announce Partnership to Deliver Proton and Carbon-Ion Dosimetry Audits Worldwide

Athens, Greece / Pavia, Italy — December 11, 2025

RTsafe is delighted to announce a new partnership with CNAO Next s.r.l., the services and innovation arm of Fondazione CNAO, to jointly deliver independent proton and carbon-ion dosimetry audits for hadron therapy centers around the world.

Through this partnership, RTsafe will extend its certified dosimetry services into proton and carbon-ion beams, supported by CNAO Next and CNAO’s medical physics expertise. Both organizations will collaborate on proton and carbon-ion therapy end-to-end audits and related dosimetry and consulting services, enabling a new global standard of quality assurance in particle therapy.

The collaboration includes:

• Joint implementation of proton and carbon-ion dosimetry audit services for third-party clinical centers.
• Access for RTsafe to CNAO’s synchrotron facility for device testing and protocol development.
• A coordinated framework ensuring that audit activities are performed together, with RTsafe responsible for certification and delivery, and CNAO Next providing technical and clinical support.

RTsafe Founder & CSO Evangelos Pappas said:
“This partnership with CNAO Next strengthens RTsafe’s mission to enhance radiotherapy safety. Together we will enable reliable, independent proton and carbon-ion dosimetry audits—critical tools for every hadron therapy center.”

CNAO Next CEO Maria Vittoria Livraga added:
“We are proud to support RTsafe in expanding high-quality audit services. This partnership contributes directly to the safe growth of hadron therapy worldwide. We also invite clinical centers and technology partners interested in elevating quality standards in hadrontherapy to explore collaboration opportunities with us.”

Enabling the Future of Hadron Therapy Quality Assurance

Hadron therapy—particularly carbon-ion therapy—is rapidly expanding due to its unmatched dose-conformity and biological effectiveness. Ensuring independent, high-fidelity dosimetry is a critical component of this growth. Through this collaboration:

• RTsafe gains access to one of the world’s most advanced proton and carbon-ion synchrotron facilities for device testing and protocol optimization.
• CNAO Next contributes its clinical, technical, and dosimetric expertise, developed over more than a decade of hadron-therapy operations.
• Global therapy centers will benefit from new end-to-end QA tools and audit programs tailored for particle-beam treatments.

Both RTsafe and CNAO Next will also co-author scientific publications arising from the testing activities, further advancing knowledge within the field.

This strategic partnership creates a unified pathway for delivering robust, high-precision QA and consulting services to current and future proton and carbon-ion centers, reinforcing both organizations’ commitment to patient safety and treatment excellence.

This strategic partnership creates a unified pathway for delivering robust, high-precision QA and consulting services to current and future proton and carbon-ion centers, reinforcing both organizations’ commitment to patient safety and treatment excellence.

Press to download the Press Release

For media inquiries, please contact: Ms. Marianna Liondou, [email protected]

About RTsafe

RTsafe is a medical technology company committed to improving the safety and effectiveness of radiotherapy worldwide. Through patient-specific 3D dosimetry, anthropomorphic phantoms, and independent auditing services, RTsafe supports clinics in optimizing treatment accuracy and enhancing patient outcomes. Learn more at www.rt-safe.com.

About CNAO and CNAO Next

Fondazione CNAO is one of Europe’s leading centers for oncological hadrontherapy, equipped with a state-of-the-art synchrotron capable of delivering proton and carbon-ion treatments. CNAO has gained a unique experience over the course of 15 years in treating patients with hadrontherapy. CNAO Next, its wholly owned subsidiary, provides clinical, technical, research, and advisory services aimed at supporting the growth of particle therapy internationally.